EHA 2015 | ENDEAVOR trial: Carfilzomib and dexamethasone for relapsed multiple myeloma

Jesús San Miguel

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicenter, open-label, randomized, phase 3 ENDEAVOR trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed multiple myeloma.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter